WO2011151814A3 - Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications - Google Patents

Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications Download PDF

Info

Publication number
WO2011151814A3
WO2011151814A3 PCT/IL2011/000413 IL2011000413W WO2011151814A3 WO 2011151814 A3 WO2011151814 A3 WO 2011151814A3 IL 2011000413 W IL2011000413 W IL 2011000413W WO 2011151814 A3 WO2011151814 A3 WO 2011151814A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
penetrating peptide
diagnostic
therapeutic applications
cell penetrating
Prior art date
Application number
PCT/IL2011/000413
Other languages
French (fr)
Other versions
WO2011151814A2 (en
Inventor
Ayelet David
Gonen Ashkenasy
Yossi Shamay
Original Assignee
Ben-Gurion University Of The Negev Research And Development Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben-Gurion University Of The Negev Research And Development Authority filed Critical Ben-Gurion University Of The Negev Research And Development Authority
Priority to EP11789344.6A priority Critical patent/EP2575848A4/en
Priority to CA2800153A priority patent/CA2800153A1/en
Priority to US13/700,847 priority patent/US10167319B2/en
Publication of WO2011151814A2 publication Critical patent/WO2011151814A2/en
Publication of WO2011151814A3 publication Critical patent/WO2011151814A3/en
Priority to IL223318A priority patent/IL223318A0/en
Priority to US16/205,275 priority patent/US10947275B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids

Abstract

The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticulate pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.
PCT/IL2011/000413 2010-05-29 2011-05-26 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications WO2011151814A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP11789344.6A EP2575848A4 (en) 2010-05-29 2011-05-26 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
CA2800153A CA2800153A1 (en) 2010-05-29 2011-05-26 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
US13/700,847 US10167319B2 (en) 2010-05-29 2011-05-26 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
IL223318A IL223318A0 (en) 2010-05-29 2012-11-28 Caged cell penetrating peptide-polymer conjugates, compositions comprising the same and uses thereof
US16/205,275 US10947275B2 (en) 2010-05-29 2018-11-30 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34981910P 2010-05-29 2010-05-29
US61,349,819 2010-05-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/700,847 A-371-Of-International US10167319B2 (en) 2010-05-29 2011-05-26 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
US16/205,275 Continuation US10947275B2 (en) 2010-05-29 2018-11-30 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications

Publications (2)

Publication Number Publication Date
WO2011151814A2 WO2011151814A2 (en) 2011-12-08
WO2011151814A3 true WO2011151814A3 (en) 2012-03-29

Family

ID=45067148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2011/000413 WO2011151814A2 (en) 2010-05-29 2011-05-26 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications

Country Status (4)

Country Link
US (2) US10167319B2 (en)
EP (1) EP2575848A4 (en)
CA (1) CA2800153A1 (en)
WO (1) WO2011151814A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151814A2 (en) * 2010-05-29 2011-12-08 Ben-Gurion University Of The Negev Research And Development Authority Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
WO2014197816A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
CN108283721B (en) * 2018-02-08 2020-05-05 重庆医科大学 HA-mediated CPPs modified 10-HCPT-loaded phase change lipid nanoparticle and preparation method thereof
WO2019226651A1 (en) * 2018-05-22 2019-11-28 Children's Medical Center Corporation Nanoparticles for treatment of choroidal neovascularization and other indications
WO2023067366A1 (en) * 2021-10-18 2023-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Photoactivatable ion channel modulator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318246A1 (en) * 2007-03-07 2008-12-25 The Albert Einstein College Of Medicine Of Yeshiva University Deeply quenched enzyme sensors
US20090186802A1 (en) * 2005-12-16 2009-07-23 Diatos Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell
US20100111949A1 (en) * 2007-03-30 2010-05-06 Xuebin Qin Methods and compositions for the treatment of proliferative diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593148B1 (en) 1994-03-01 2003-07-15 Li-Cor, Inc. Cyanine dye compounds and labeling methods
US6027709A (en) 1997-01-10 2000-02-22 Li-Cor Inc. Fluorescent cyanine dyes
DE60116510T2 (en) 2000-09-19 2006-07-13 Li-Cor, Inc., Lincoln cyanine
EP1472351B1 (en) * 2002-02-07 2007-06-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US7005518B2 (en) 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
WO2004046339A2 (en) * 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
AU2004213752B2 (en) * 2003-01-31 2008-10-23 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2005065418A2 (en) 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
JP5043672B2 (en) * 2005-10-28 2012-10-10 田辺三菱製薬株式会社 Novel cell membrane penetrating peptide
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1797901A1 (en) * 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
MX2008014337A (en) 2006-05-12 2009-06-17 Univ Texas Imaging agents and methods.
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
EP2274017B1 (en) 2008-04-30 2016-04-13 Ben Gurion University Of The Negev Research And Development Authority E-selectin specific vascular delivery systems
US8546320B2 (en) * 2008-11-14 2013-10-01 Kyoto University Hsp9O-targeted anti-cancer chimeric peptide
WO2011151814A2 (en) * 2010-05-29 2011-12-08 Ben-Gurion University Of The Negev Research And Development Authority Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186802A1 (en) * 2005-12-16 2009-07-23 Diatos Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell
US20080318246A1 (en) * 2007-03-07 2008-12-25 The Albert Einstein College Of Medicine Of Yeshiva University Deeply quenched enzyme sensors
US20100111949A1 (en) * 2007-03-30 2010-05-06 Xuebin Qin Methods and compositions for the treatment of proliferative diseases

Also Published As

Publication number Publication date
CA2800153A1 (en) 2011-12-08
WO2011151814A2 (en) 2011-12-08
US10167319B2 (en) 2019-01-01
US20140017169A1 (en) 2014-01-16
US10947275B2 (en) 2021-03-16
US20190225653A1 (en) 2019-07-25
EP2575848A2 (en) 2013-04-10
EP2575848A4 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
WO2012101639A3 (en) Nanoparticles based for dermal and systemic delivery of drugs
WO2011151814A3 (en) Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
WO2011116963A3 (en) Lipid nanoparticle capsules
EP3000481A3 (en) Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier
WO2012054500A3 (en) Compositions for drug administration
WO2017044894A3 (en) Cartilage-homing peptides
WO2011119995A3 (en) Formulations and methods of use
WO2009114776A3 (en) Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
PH12014502778A1 (en) Antibody formulation
WO2014014613A3 (en) Self-assembling peptides, peptide nanostructures and uses thereof
MY166518A (en) Nanocapsules containing microemulsions
WO2012137150A3 (en) Cell penetrating peptides for intracellular delivery of molecules
MA34832B1 (en) BIODEGRADABLE DRUG DELIVERY COMPOSITIONS
WO2011131896A3 (en) Peptide derivatives, preparation thereof and uses thereof as vectors
WO2010128504A3 (en) Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
EP3626253A3 (en) Stable formulations of linaclotide
WO2011106309A3 (en) Materials and methods for mri contrast agents and drug delivery
WO2015081096A3 (en) Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2009135853A3 (en) Encapsulation of biologically active agents
CA2892965C (en) Lyophilized formulation of tat-nr2b9c
WO2011071280A3 (en) Intracelluar targeting bipodal peptide binder
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2012040331A3 (en) Multistage nanoparticles

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2800153

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 223318

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011789344

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011789344

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13700847

Country of ref document: US